Claims
- 1. A compound of formula I whereinR1 and R2 independently are hydrogen, halogen, trifluoromethyl, NR6R7, hydroxy, C1-6-alkyl or C1-6-alkoxy wherein R6 and R7 independently are hydrogen or C1-6-alkyl; Y is >CH—CH2— or >C═CH— wherein only the underscored atom participates in the ring system; X is —CH2CH2—, —CH2—(C═O)—, —(C═O)—CH2—, or —CH═CH—; r is 1, 2 or 3; and Z is whereinR3 is —(CH2)pCOR4 wherein p is 0 or 1 and R4 is —OH, —NH2, —NHOH or C1-6-alkoxy; R5 is hydrogen, halogen, trifluoromethyl, hydroxy, C1-6-alkyl or C1-6-alkoxy; R10 is hydrogen, C1-6-alkyl, C1-6-alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C1-6-alkyl or C1-6-alkoxy; and . . . is a single or double bond; or a pharmaceutically acceptable salt thereof.
- 2. A compound according to claim 1, wherein R1 and R2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C1-6-alkyl or C1-6-alkoxy.
- 3. A compound according to claim 2, wherein X is —CH2CH2—.
- 4. A compound according to claim 2, wherein X is —CH═CH—.
- 5. A compound according to claim 2, wherein Z is
- 6. A compound according to claim 1 which is:1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid; (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxamide; 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid; 1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl-4-piperidinecarboxylic acid; (R)-1-(3-(10,11-Dihydro-5H-dibenzo [a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid; (S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid; or a pharmaceutically acceptable salt thereof.
- 7. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically carrier or diluent.
- 8. The pharmaceutical composition according to claim 7, wherein the compound is present in an amount of between 0.5 mg and 1000 mg per unit dose.
- 9. A method of treating neuropathy, migraine, neurogenic inflammation, or rheumatoid arthritis in a subject in need of such treatment comprising administering to the subject an effective amount of a compound according to claim 1.
- 10. A method of treating neuropathy, migraine, neurogenic inflammation, or rheumatoid arthritis in a subject in need of such treatment comprising administering to the subject an effective amount of a pharmaceutical composition according to claim 7.
Priority Claims (4)
Number |
Date |
Country |
Kind |
0019/94 |
Jan 1994 |
DK |
|
1290/94 |
Nov 1994 |
DK |
|
0405/95 |
Apr 1995 |
DK |
|
1005/95 |
Sep 1995 |
DK |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. application Ser. Nos. 08/623,289 filed Mar. 28, 1996, now U.S. Pat. No. 5,874,428, and 08/544,682 filed Oct. 18, 1995 now U.S. Pat. No. 5,795,888 which is a division of application Ser. No. 08/367,648 filed Jan. 3, 1995, now U.S. Pat. No. 5,595,989, which claims priority under 35 U.S.C. 119 of Danish applications 1005/95 filed Sep. 11, 1995; 0405/95 filed Apr. 7, 1995; 0019/94 filed on Jan. 4, 1994; and 1290/94 filed on Nov. 9, 1994, the contents of which are fully incorporated herein by reference.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5595989 |
Anderson et al. |
Jan 1997 |
|
5795888 |
Andersen et al. |
Aug 1998 |
|
5874428 |
Dorwald et al. |
Feb 1999 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08/623289 |
Mar 1996 |
US |
Child |
09/055574 |
|
US |
Parent |
08/544682 |
Oct 1995 |
US |
Child |
08/623289 |
|
US |